Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.37 |
| ▸ | TTK | P33981 | 3/20 | 0.36 |
| ▸ | CCNC | P24863 | 2/20 | 0.36 |
| ▸ | CDK8 | P49336 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CD38 | P28907 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579667 | 0.81 | CCNC (0.45) | PIM1CCNCCDK8 | |
| SCHEMBL14287007 | 0.79 | SMYD3 (0.40) | PIM1SMYD3CCNCCDK8HSD11B1 | |
| SCHEMBL4580627 | 0.76 | SMYD3 (0.42) | PIM1SMYD3CCNCCDK8SCN9A | |
| SCHEMBL4580790 | 0.74 | ALDH1A1 (0.49) | SCN9A | |
| SCHEMBL15743029 | 0.73 | CNR1 (0.54) | CCNCCDK8CNR1 | |
| SCHEMBL4581027 | 0.69 | CCNC (0.44) | PIM1SMYD3CCNCCDK8 | |
| SCHEMBL4581731 | 0.68 | SMYD3 (0.40) | PIM1SMYD3CCNCCDK8CNR1 | |
| SCHEMBL4579997 | 0.68 | KDM4E (0.41) | PIM1SMYD3CCNCCDK8 | |
| SCHEMBL4579031 | 0.67 | CNR1 (0.45) | CNR1 | |
| SCHEMBL4582871 | 0.66 | PRKAA2 (0.60) | PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | SERENEX, INC. | 2008-02-07 | — | — | US | claimed |
| US-7282506-B2 | 2,8-disubstituted naphthyridine derivatives | SERENEX, INC. (US) | 2007-10-16 | — | — | US | claimed |
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | SERENEX, INC. | 2006-02-09 | — | — | US | claimed |
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | SERENEX, INC. | 2008-02-07 | — | — | US | disclosed |
| US-7282506-B2 | 2,8-disubstituted naphthyridine derivatives | SERENEX, INC. (US) | 2007-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030584-A1 | 2,8-Disubstituted naphthyridine derivatives | CCNA1, FOXM1, CCNA2 | PIM1 3356/4885SMYD3 3067/4885TTK 4375/4885 |
| US-20080032991-A1 | 2, 8-disubstituted Naphthyridine Derivatives | CCNA1, FOXM1, CCNA2 | PIM1 3356/4885SMYD3 3067/4885TTK 4375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.